|
1
|
Laitinen M, Parry M, Ratasvuori M, Wedin
R, Albergo JI, Jeys L, Abudu A, Carter S, Gaston L, Tillman R and
Grimer R: Survival and complications of skeletal reconstructions
after surgical treatment of bony metastatic renal cell carcinoma.
EJSO the Journal Cancer Surgery. 41:886–892. 2015.
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rasmussen F: Metastatic renal cell cancer.
Cancer Imaging. 13:374–380. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rouvière O, Bouvier R, Négrier S, Badet L
and Lyonnet D: Nonmetastatic renal-cell carcinoma: Is it really
possible to define rational guidelines for post-treatment
follow-up? Nat Clin Pract Oncol. 3:200–213. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bianchi M, Sun M, Jeldres C, Shariat SF,
Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P,
et al: Distribution of metastatic sites in renal cell carcinoma: A
population-based analysis. Ann Oncol. 23:973–980. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang Q, Zhang W, Yang J, Liu YL, Yan ZX,
Guo ZJ, Li YJ and Bian XW: High ERα36 Expression level and membrane
location predict poor prognosis in renal cell carcinoma. Medicine
(Baltimore). 94:e10482015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang HM, Yang FQ, Chen SJ, Che J and
Zheng JH: Upregulation of long non-coding RNA MALAT1 correlates
with tumor progression and poor prognosis in clear cell renal cell
carcinoma. Tumour Biol. 36:2947–2955. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schaefer A, Jung M, Kristiansen G, Lein M,
Schrader M, Miller K, Stephan C and Jung K: MicroRNAs and cancer:
Current state and future perspectives in urologic oncology. Urol
Oncol. 28:4–13. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mu YP, Tang S, Sun WJ, Gao WM, Wang M and
Su XL: Association of miR-193b down-regulation and mir-196a
up-regulation with clinicopathological features and prognosis in
gastric Cancer. Asian Pac J Cancer Prev. 15:8893–9000. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shao C, Yu Y, Yu L, Pei Y, Feng Q, Chu F,
Fang Z and Zhou Y: Amplification and up-regulation of microRNA-30b
in oral squamous cell cancers. Arch Oral Biol. 57:1012–1017. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu YC, Chang JT, Huang YC, Huang CC, Chen
WH, Lee LY, Huang BS, Chen YJ, Li HF and Cheng AJ: Combined
determination of circulating miR-196a and miR-196b levels produces
high sensitivity and specificity for early detection of oral
cancer. Clin Biochem. 48:115–121. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qiao F, Zhang K, Gong P, Wang L, Hu J, Lu
S and Fan H: Decreased miR-30b-5p expression by DNMT1 methylation
regulation involved in gastric cancer metastasis. Mol Biol Rep.
41:5693–5700. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen S, Li P, Yang R, Cheng R, Zhang F,
Wang Y, Chen X, Sun Q, Zang W, Du Y, et al: microRNA-30b inhibits
cell invasion and migration through targeting collagen triple helix
repeat containing 1 in non-small cell lung cancer. Cancer Cell Int.
15:852015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao H, Xu Z, Qin H, Gao Z and Gao L:
miR-30b regulates migration and invasion of human colorectal cancer
via SIX1. Biochem J. 460:117–125. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu ED, Li N, Li BS, Li W, Zhang WJ, Mao
XH, Guo G, Zou QM and Xiao B: miR-30b, down-regulated in gastric
cancer, promotes apoptosis and suppresses tumor growth by targeting
plasminogen activator inhibitor-1. PLoS One. 9:e1060492014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ge YZ, Wu R, Xin H, Zhu M, Lu TZ, Liu H,
Xu Z, Yu P, Zhao YC, Li MH, et al: A tumor-specific microRNA
signature predicts survival in clear cell renal cell carcinoma. J
Cancer Res Clin Oncol. 141:1291–1299. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wulfken LM, Moritz R, Ohlmann C,
Holdenrieder S, Jung V, Becker F, Herrmann E, Walgenbach-Brünagel
G, von Ruecker A, Müller SC and Ellinger J: MicroRNAs in renal cell
carcinoma: Diagnostic implications of serum miR-1233 levels. PLoS
One. 6:e257872011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang ZX, Li JL, Cao JX, Liu YS, Li D,
Zhang XY, Wang M, Wu M, Xu BL, Liu JL, et al: Cytokine-induced
killer cells in the treatment of patients with renal cell
carcinoma: A pooled meta-analysis. Immunotherapy. 6:787–795. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu M, Tang Q, Qiu M, Lang N, Li M, Zheng
Y and Bi F: miR-21 targets the tumor suppressor RhoB and regulates
proliferation, invasion and apoptosis in colorectal cancer cells.
FEBS Lett. 585:2998–3005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhong K, Chen K, Han L and Li B:
MicroRNA-30b/c inhibits non-small cell lung cancer cell
proliferation by targeting Rab18. BMC Cancer. 14:7032014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tian SB, Yu JC, Liu YQ, Kang WM, Ma ZQ, Ye
X and Yan C: MiR-30b suppresses tumor migration and invasion by
targeting EIF5A2 in gastric cancer. World J Gastroenterol.
21:9337–9347. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mahdavinezhad A, Mousavi-Bahar SH,
Poorolajal J, Yadegarazari R, Jafari M, Shabab N and Saidijam M:
Evaluation of miR-141, miR-200c, miR-30b Expression and
Clinicopathological Features of Bladder Cancer. Int J Mol Cell Med.
4:32–39. 2015.PubMed/NCBI
|
|
24
|
Lu Y, Ryan SL, Elliott DJ, Bignell GR,
Futreal PA, Ellison DW, Bailey S and Clifford SC: Amplification and
overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at
8q24.22-q24.23 in medulloblastoma. PLoS One. 4:e61592009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Heinzelmann J, Henning B, Sanjmyatav J,
Posorski N, Steiner T, Wunderlich H, Gajda MR and Junker K:
Specific miRNA signatures are associated with metastasis and poor
prognosis in clear cell renal cell carcinoma. World J Urol.
29:367–373. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gu YF, Zhang H, Su D, Mo ML, Song P, Zhang
F and Zhang SC: miR-30b and miR-30c expression predicted response
to tyrosine kinase inhibitors as first line treatment in non-small
cell lung cancer. Chin Med J (Engl). 126:4435–4439. 2013.PubMed/NCBI
|
|
27
|
Liao WT, Ye YP, Zhang NJ, Li TT, Wang SY,
Cui YM, Qi L, Wu P, Jiao HL, Xie YJ, et al: MicroRNA-30b functions
as a tumour suppressor in human colorectal cancer by targeting
KRAS, PIK3CD and BCL2. J Pathol. 232:415–427. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bridge G, Monteiro R, Henderson S, Emuss
V, Lagos D, Georgopoulou D, Patient R and Boshoff C: The
microRNA-30 family targets DLL4 to modulate endothelial cell
behavior during angiogenesis. Blood. 120:5063–5072. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fuster O, Llop M, Dolz S, García P, Such
E, Ibáñez M, Luna I, Gómez I, López M, Cervera J, et al: Adverse
prognostic value of MYBL2 overexpression and association with
microRNA-30 family in acute myeloid leukemia patients. Leuk Res.
37:1690–1696. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li L and Wang B: Overexpression of
microRNA-30b improves adenovirus-mediated p53 cancer gene therapy
for laryngeal carcinoma. Int J Mol Sci. 15:19729–19740. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ichikawa T, Sato F, Terasawa K, Tsuchiya
S, Toi M, Tsujimoto G and Shimizu K: Trastuzumab produces
therapeutic actions by upregulating miR-26a and miR-30b in breast
cancer cells. PLoS One. 7:e314222012. View Article : Google Scholar : PubMed/NCBI
|
